A newly developed vaccine for glioblastoma shows 'remarkable' promise, according to preliminary results from a study of the treatment. Patients with the disease typically die within 2 years. Some in the trial have now lived as long as 7 years.
A newly developed vaccine for glioblastoma shows 'remarkable' promise, according to preliminary results from a study of the treatment. Patients with the disease typically die within 2 years. Some in the trial have now lived as long as 7 years. Evan Vucci AP
A newly developed vaccine for glioblastoma shows 'remarkable' promise, according to preliminary results from a study of the treatment. Patients with the disease typically die within 2 years. Some in the trial have now lived as long as 7 years. Evan Vucci AP

Scientists created a brain-cancer vaccine - and so far it's 'remarkably promising'

May 30, 2018 11:20 AM